Eledon Pharmaceuticals

Update in progress

ELDN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the CD40L pathway to protect transplanted organs, prevent rejection, and treat ALS. Its lead candidate, tegoprubart, is an IgG1 anti-CD40L antibody with high affinity. It targets kidney allograft rejection and xenotransplantation programs and develops NCEL-101 for Type 1 diabetes with NewcelX. Formerly Novus Therapeutics; based in Irvine, California.

Company score

Sentiment: 0.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEODr. David-Alexandre C. Gros M.D., Ph.D.
Employees33
Websiteeledon.com

Identifiers

ISINUS28617K1016
FIGIBBG00241S542
CUSIP28617K101
CIK0001404281